Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The objectives of this study are:

• To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers

• To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: CJ HealthCare Corporation; HK inno.N Corporation
• Treatments: Amlodipine; Amlodipine, Valsartan Drug Combination; Lactitol; Valsartan

Criteria

Inclusion Criteria:

• Male volunteers in the age between 20 and 45 years old

• Body Mass Index (BMI) in the range of 19 to 27 kg/m2

Exclusion Criteria:

• History of allergy or sensitivity to any drug, including amlodipine or valsartan

• History of clinically significant hepatic, renal, gastrointestinal, neurology, pulmonary, endocrine, musculoskeletal, hematologic, oncologic, psychiatric, especially cardiovascular disease

• History of surgery except or gastrointestinal diseases which might significantly change absorption of medicines

• Hypotension (Systolic Blood Pressure(SBP) ≤ 100 mmHg or Diastolic Blood Pressure(DBP) ≤ 65 mmHg)

• Hypertension (SBP ≥ 150 mmHg or DBP ≥ 95 mmHg)

• Clinical laboratory test values are outside the accepted normal range

• Aspartate Transaminase(AST) or Alanine Transaminase(ALT) > 1.25 times to normal range

• Total bilirubin > 1.25 times to normal range

• Positive for Hepatitis B Virus surface Antigen(HBsAg), Hepatitis C Virus Antibody(HCVAb) or Human Immunodeficiency Virus Antibody(HIVAb)